Prognostic significance of cathepsin-D in patients with breast cancer
1993

Cathepsin-D and Breast Cancer Prognosis

Sample size: 359 publication Evidence: moderate

Author Information

Author(s): J.H.R. Winstanley, S.J. Leinster, T.G. Cooke, B.R. Westley, A.M. Platt-Higgins, P.S. Rudland

Primary Institution: University of Liverpool Medical School

Hypothesis

Does the expression of cathepsin-D in breast cancer tissues correlate with patient survival outcomes?

Conclusion

Higher levels of cathepsin-D expression are associated with poorer survival in breast cancer patients.

Supporting Evidence

  • 35% of patients showed strong cathepsin-D staining.
  • Patients with cathepsin-D positive tumors had a median survival of 147 months compared to 180 months for negative tumors.
  • The presence of cathepsin-D was significantly associated with axillary lymph node involvement.

Takeaway

This study found that patients with higher levels of a protein called cathepsin-D in their breast cancer tissues tend to live for a shorter time.

Methodology

The study used immunohistochemical techniques to evaluate cathepsin-D expression in paraffin-embedded tissue samples from breast cancer patients.

Potential Biases

Potential interobserver variability in staining assessment could affect results.

Limitations

The study's findings may be influenced by the presence of other prognostic factors and the variability in staining assessment.

Participant Demographics

Patients had a mean age of 57 years, with a range from 29 to 92 years.

Statistical Information

P-Value

0.025

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication